pp-209 Solution for infusion

Indication: Acute ischaemic stroke (AIS) in patients with large vessel occlusion (LVO) undergoing endovascular thrombectomy (EVT) Clinical stage: Phase 2 Modality: Biological (novel Smart Growth Factor™ — modified IGF-1 fusion protein — NBE) Mechanism / Target: Proprietary Smart Growth Factor™ platform; modified IGF-1 protein engineered to selectively bind and deliver IGF-1 to injured/ischaemic neurons via targeted delivery mechanism; promotes neuroprotection and neuroregeneration in the stroke penumbra; selectively delivered to injured cells, avoiding systemic IGF-1 effects Route / form: IV infusion (administered up to 24 hours post-stroke onset) Differentiation: First targeted neuroprotectant in Phase 2 for ischaemic stroke; selectively delivers IGF-1 to injured neural cells — avoids systemic hypoglycaemia;